In vitro antiprogestational/antiglucocorticoid activity and progestin and glucocorticoid receptor binding of the putative metabolites and synthetic derivatives of CDB-2914, CDB-4124, and mifepristone

@article{Attardi2004InVA,
  title={In vitro antiprogestational/antiglucocorticoid activity and progestin and glucocorticoid receptor binding of the putative metabolites and synthetic derivatives of CDB-2914, CDB-4124, and mifepristone},
  author={Barbara J. Attardi and Janet Burgenson and Sheri Ann Hild and Jerry R. Reel},
  journal={The Journal of Steroid Biochemistry and Molecular Biology},
  year={2004},
  volume={88},
  pages={277-288}
}
In determining the biological profiles of various antiprogestins, it is important to assess the hormonal and antihormonal activity, selectivity, and potency of their proximal metabolites. The early metabolism of mifepristone is characterized by rapid demethylation and hydroxylation. Similar initial metabolic pathways have been proposed for CDB-2914 (CDB: Contraceptive Development Branch of NICHD) and CDB-4124, and their putative metabolites have been synthesized. We have examined the functional… Expand
Synthesis and antiprogestational properties of novel 17-fluorinated steroids
TLDR
The representative antiprogestin EC304 was found to inhibit in vitro tumorigenicity in a dose-dependent fashion in T47D cells by a colony formation assay at 1 and 10nM concentrations and was demonstrated in an antinidation assay for the interruption of early pregnancy in rats. Expand
Molecular determinants of the recognition of ulipristal acetate by oxo-steroid receptors
TLDR
A structural approach to characterizing the binding of UPA to the oxo-steroid receptors at the molecular level revealed that the network of stabilizing contacts between the UPA C11 aryl group and the LBD is responsible for its high PR antagonist potency. Expand
Genomic and Nongenomic Effects of Mifepristone at the Cardiovascular Level: A Review
TLDR
The main purpose of this review is to describe the genomic and nongenomic effects of mifepristone at vascular level and describe some pathologies in which mifEPristone is used as a treatment. Expand
Recent advances in structure of progestins and their binding to progesterone receptors
TLDR
The aim of this review is to describe the basic structure of PR agonists and antagonists as well as the recent treatments for illness associated with the progesterone receptor. Expand
Dimethandrolone (7α,11β-dimethyl-19-nortestosterone) and 11β-methyl-19-nortestosterone are not converted to aromatic A-ring products in the presence of recombinant human aromatase
TLDR
Data support the notion that in the absence of the C19-methyl group, aromatization of androgenic substrates proceeds slowly or not at all and that this reaction is impeded by the presence of a methyl group at the 11beta position. Expand
Method of molecular docking in the design of new progesterone analogues
The aim of this study is to carry out the molecular docking of gestagenic preparations and structurally related compounds to the isoform A of human progesterone receptor and to assess theExpand
The modulatory role of androgens and progestins in the induction of vasorelaxation in human umbilical artery.
TLDR
Investigation of the vasorelaxant properties of several progestins and androgens on the vascular tone of human umbilical artery to elucidate their potential regulatory role on fetoplacental blood flow suggests that sex steroids (particularly androgens) induce an acute (nongenomically-mediated) vasore laxing effect on the HUA. Expand
Selective progesterone receptor modulators-mechanisms and therapeutic utility.
TLDR
Mifepristone, ulipristal acetate, vilaprisan, and asoprisnil effectively treated heavy menstrual bleeding in patients with uterine fibroids, but limited data exist regarding the efficacy of SPRMs for HMB outside this context. Expand
Population Pharmacokinetics of Telapristone (CDB-4124) and its Active Monodemethylated Metabolite CDB-4453, with a Mixture Model for Total Clearance
TLDR
A two-compartment parent-metabolite model adequately described the pharmacokinetics of telapristone and CDB-4453 and could be the result of metabolism via polymorphic CYP3A5. Expand
Mechanism of Telapristone Acetate (CDB4124) on Progesterone Receptor Action in Breast Cancer Cells.
TLDR
Investigation of the molecular mechanism by which TPA antagonizes PR action demonstrates that treatment with the progestin (R5020) alone resulted in robust PR recruitment to the chromatin, and addition of TPA reduced PR recruitment globally. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 27 REFERENCES
CDB-4124 and its putative monodemethylated metabolite, CDB-4453, are potent antiprogestins with reduced antiglucocorticoid activity: in vitro comparison to mifepristone and CDB-2914
TLDR
While there was a good correlation between binding to PR and functional activity of these antiprogestins, GR binding was not predictive of their glucocorticoid antagonist activity. Expand
Screening of anti-progestagens by receptor studies and bioassays.
TLDR
Two compounds tested with the dimethylaminophenyl group at carbon atom 18 of 17 beta-hydroxy-17 alpha-(2-propenyl)-estra-4-en-3-one are equipotent with RU 38486 in the pregnancy interruption test, and it is very likely that they become activated in the gastro-intestinal tract. Expand
RU486 (mifepristone): mechanisms of action and clinical uses.
TLDR
Clinically, the RU486-plus-prostaglandin method is close to being as convenient and safe as any medical method of abortion may be and the early use of RU486 as a contragestive as soon as a woman fears a pregnancy she does not want will help to defuse the abortion issue. Expand
Analysis of the relation between receptor binding affinity and antagonist efficacy of antiglucocorticoids.
TLDR
It is shown that in all cases, in the presence or absence of antiglucocorticoids, a specific TAT induction level was always related to the same level of receptor saturation by the agonist in whole cells. Expand
Pharmacologic properties of CDB(VA)-2914
TLDR
The results of metabolism studies undertaken to link the results of the animal models to potential human applications show that CDB(VA)-2914 is a promising candidate for use in contraception as well as treatment of uterine fibroids and endometriosis. Expand
Clinical Pharmacokinetics of Mifepristone
TLDR
The 3 most proximal metabolites of mifepristone all retain considerable affinity toward the human progesterone and glucocorticoid receptors; in addition, the serum concentrations of these 3 metabolites are in a similar range as those of the parent drug. Expand
Estrogenic and progestagenic activities coexisting in steroidal drugs: Quantitative evaluation by In vitro bioassays with human cells
TLDR
The reduced capability of the partial agonists to exert progestagenic or estrogenic effects on AP expression may reflect an impeded, receptor-mediated action, a mechanism that would also account for their inhibitory effects on the induction of AP activity by full agonists. Expand
The antiprogestin RU38 486: receptor-mediated progestin versus antiprogestin actions screened in estrogen-insensitive T47Dco human breast cancer cells.
TLDR
The use of T47Dco human breast cancer cells are used to assess the receptor-binding properties and the biological actions of RU38 486, a candidate antiprogestin that has dual progestin agonist/antagonist actions depending on the biological response measured. Expand
CDB-2914: anti-progestational/anti-glucocorticoid profile and post-coital anti-fertility activity in rats and rabbits.
TLDR
Data demonstrate that CDB-2914 is a potent, orally active anti-progestin with weak anti-glucocorticoid activity and inhibited implantation in adult rats and rabbits demonstrating its potential as a post-coital contraceptive drug. Expand
Identification of CYP3A4 as the principal enzyme catalyzing mifepristone (RU 486) oxidation in human liver microsomes.
TLDR
Data clearly support CYP3A4 as the enzyme primarily responsible for mifepristone demethylation and hydroxylation in human liver microsomes. Expand
...
1
2
3
...